Promising approaches include enhancing mitochondrial quality control (e.g., PINK1/Parkin activators), modulating neuroinflammation (e.g., TREM2 agonists and cGAS-STING inhibitors), and developing PIAS2-targeted therapies for specific PD subtypes. Here, PRKN is linked to Parkinson disease.